Endothelial Cell Molecular and Metabolic Heterogeneity in Pulmonary Arterial Hypertension

Project description

Identifying the cellular perpetrator behind pulmonary hypertension

Most people likely think about blood pressure cuffs when hypertension is mentioned, but the large arteries carrying de-oxygenated blood from the heart to the lungs are also susceptible. Pulmonary arterial hypertension (PAH) is a rare progressive disorder for which there is treatment but no cure. The exact cause is unknown but research points to endothelial cells lining the small blood vessels of the lung and a role in vascular remodelling. The EU-funded EMPAtHy project is studying differences in metabolic gene expression among subpopulations of endothelial cells in PAH. Comparing effects of a new metabolic therapy on patients and on these subsets of cells could provide a clue as to which cells do what when it comes to PAH.

Programme(s)

• H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility

Topic(s)

• MSCA-IF-2018 - Individual Fellowships

Call for proposal

H2020-MSCA-IF-2018
See other projects for this call

Funding Scheme

MSCA-IF-EF-ST - Standard EF

Coordinator

VIB VZW

Address

Rijvisschestraat 120
9052 Zwijnaarde - Gent
Belgium

Activity type

Research Organisations

EU contribution

€ 166 320